Actio locks in $55M Series A raise to advance rare disease pipeline based on human genetic platform

Reynald Castañeda

Deputy Editor

Actio Biosciences has secured a Series A raise worth $55 million to advance its clinical pipeline in rare diseases, particularly in patients with ion channel …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Actio locks in $55M Series A raise to advance rare disease pipeline based on human genetic platform

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Biotech VC firm outlines plans for $100M fund

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Breaking down silos with a new quantitative approach to drug development

Ac­tio locks in $55M Se­ries A raise to ad­vance rare dis­ease pipeline based on hu­man ge­net­ic plat­form

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

No­vo says its CB1 drug helped shed weight, but ef­fi­ca­cy and safe­ty ques­tions re­main

FTC to sue ma­jor PBMs over in­sulin re­bates, claim­ing they in­flat­ed pa­tient cost

Biotech VC firm out­lines plans for $100M fund

Sanofi's BTK in­hibitor again slows MS pro­gres­sion, but liv­er en­zymes con­tin­ue to be tricky

Lex­i­con's pres­i­dent to step down as de­ci­sion date looms; Sarep­ta wel­comes Lil­ly, GSK vet to board

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

Actio locks in $55M Series A raise to advance rare disease pipeline based on human genetic platform

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Biotech VC firm outlines plans for $100M fund

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Breaking down silos with a new quantitative approach to drug development